Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Ticagrelor increases its own potency at the P2Y12 receptor by directly changing the plasma membrane lipid order in platelets

K. Pyrshev, F. Allemand, V. Rabani, S. Yesylevskyy, S. Davani, C. Ramseyer, J. Lagoutte-Renosi

. 2024 ; 181 (21) : 4369-4380. [pub] 20240716

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25003723

Grant support
SPS 985291 North Atlantic Treaty Organization
2020.01/0043 National Research Foundation of Ukraine
European Union

E-resources Online Full text

NLK Free Medical Journals from 1968 to 1 year ago
Europe PubMed Central from 1968 to 1 year ago
Medline Complete (EBSCOhost) from 2002-01-01 to 1 year ago
Wiley Free Content from 1997 to 1 year ago

Links

PubMed 39014887
DOI 10.1111/bph.16500
Knihovny.cz E-resources

BACKGROUND AND PURPOSE: Although the amphiphilic nature of the widely used antithrombotic drug Ticagrelor is well known, it was never considered as a membranotropic agent capable of interacting with the lipid bilayer in a receptor-independent way. In this study, we investigated the influence of Ticagrelor on plasma membrane lipid order in platelets and if this modulates the potency of Ticagrelor at the P2Y12 receptor. EXPERIMENTAL APPROACH: We combined fluorescent in situ, in vitro and in silico approaches to probe the interactions between the plasma membrane of platelets and Ticagrelor. The influence of Ticagrelor on the lipid order of the platelet plasma membrane and large unilamellar vesicles was studied using the advanced fluorescent probe NR12S. Furthermore, the properties of model lipid bilayers in the presence of Ticagrelor were characterized by molecular dynamics simulations. Finally, the influence of an increased lipid order on the dose-response of platelets to Ticagrelor was studied. KEY RESULTS: Ticagrelor incorporates spontaneously into lipid bilayers and affects the lipid order of the membranes of model vesicles and isolated platelets, in a nontrivial composition and concentration-dependent manner. We showed that higher plasma membrane lipid order in platelets leads to a lower IC50 value for Ticagrelor. It is shown that membrane incorporation of Ticagrelor increases its potency at the P2Y12 receptor, by increasing the order of the platelet plasma membrane. CONCLUSION AND IMPLICATIONS: A novel dual mechanism of Ticagrelor action is suggested that combines direct binding to P2Y12 receptor with simultaneous modulation of receptor-lipid microenvironment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003723
003      
CZ-PrNML
005      
20250206104638.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bph.16500 $2 doi
035    __
$a (PubMed)39014887
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Pyrshev, Kyrylo $u Department of Neurochemistry, Palladin Institute of Biochemistry of the NAS of Ukraine, Kyiv, Ukraine $u Department of Physics of Biological Systems, Institute of Physics of the National Academy of Sciences of Ukraine, Kyiv, Ukraine $u Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center at Houston, Houston, Texas, USA
245    10
$a Ticagrelor increases its own potency at the P2Y12 receptor by directly changing the plasma membrane lipid order in platelets / $c K. Pyrshev, F. Allemand, V. Rabani, S. Yesylevskyy, S. Davani, C. Ramseyer, J. Lagoutte-Renosi
520    9_
$a BACKGROUND AND PURPOSE: Although the amphiphilic nature of the widely used antithrombotic drug Ticagrelor is well known, it was never considered as a membranotropic agent capable of interacting with the lipid bilayer in a receptor-independent way. In this study, we investigated the influence of Ticagrelor on plasma membrane lipid order in platelets and if this modulates the potency of Ticagrelor at the P2Y12 receptor. EXPERIMENTAL APPROACH: We combined fluorescent in situ, in vitro and in silico approaches to probe the interactions between the plasma membrane of platelets and Ticagrelor. The influence of Ticagrelor on the lipid order of the platelet plasma membrane and large unilamellar vesicles was studied using the advanced fluorescent probe NR12S. Furthermore, the properties of model lipid bilayers in the presence of Ticagrelor were characterized by molecular dynamics simulations. Finally, the influence of an increased lipid order on the dose-response of platelets to Ticagrelor was studied. KEY RESULTS: Ticagrelor incorporates spontaneously into lipid bilayers and affects the lipid order of the membranes of model vesicles and isolated platelets, in a nontrivial composition and concentration-dependent manner. We showed that higher plasma membrane lipid order in platelets leads to a lower IC50 value for Ticagrelor. It is shown that membrane incorporation of Ticagrelor increases its potency at the P2Y12 receptor, by increasing the order of the platelet plasma membrane. CONCLUSION AND IMPLICATIONS: A novel dual mechanism of Ticagrelor action is suggested that combines direct binding to P2Y12 receptor with simultaneous modulation of receptor-lipid microenvironment.
650    12
$a ticagrelor $x farmakologie $x chemie $7 D000077486
650    12
$a purinergní receptory P2Y12 $x metabolismus $x účinky léků $7 D058925
650    12
$a trombocyty $x účinky léků $x metabolismus $7 D001792
650    12
$a buněčná membrána $x účinky léků $x metabolismus $7 D002462
650    _2
$a lidé $7 D006801
650    _2
$a membránové lipidy $x metabolismus $7 D008563
650    _2
$a lipidové dvojvrstvy $x metabolismus $7 D008051
650    _2
$a simulace molekulární dynamiky $7 D056004
650    _2
$a antagonisté purinergních receptorů P2Y $x farmakologie $x chemie $7 D058921
655    _2
$a časopisecké články $7 D016428
700    1_
$a Allemand, Florentin $u SINERGIES, Université de Franche-Comté, Besançon, France $u CNRS, Chrono-environnement, Université de Franche-Comté, Besançon, France $1 https://orcid.org/0000000296474109
700    1_
$a Rabani, Vahideh $u SINERGIES, Université de Franche-Comté, Besançon, France
700    1_
$a Yesylevskyy, Semen $u Department of Physics of Biological Systems, Institute of Physics of the National Academy of Sciences of Ukraine, Kyiv, Ukraine $u Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry, Prague, Czech Republic $u Receptor.AI Inc, London, UK $u Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, Olomouc, Czech Republic
700    1_
$a Davani, Siamak $u Université de Franche-Comté, CHU Besançon, SINERGIES, Besançon, France
700    1_
$a Ramseyer, Christophe $u CNRS, Chrono-environnement, Université de Franche-Comté, Besançon, France
700    1_
$a Lagoutte-Renosi, Jennifer $u Université de Franche-Comté, CHU Besançon, SINERGIES, Besançon, France $1 https://orcid.org/0000000324054778
773    0_
$w MED00009383 $t British journal of pharmacology $x 1476-5381 $g Roč. 181, č. 21 (2024), s. 4369-4380
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39014887 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104634 $b ABA008
999    __
$a ok $b bmc $g 2263473 $s 1239730
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 181 $c 21 $d 4369-4380 $e 20240716 $i 1476-5381 $m British journal of pharmacology $n Br J Pharmacol $x MED00009383
GRA    __
$a SPS 985291 $p North Atlantic Treaty Organization
GRA    __
$a 2020.01/0043 $p National Research Foundation of Ukraine
GRA    __
$p European Union
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options